Piramal Pharma Limited (PPLPHARMA) Price & Analysis

Compare

11 Followers

PPLPHARMA Stock Chart & Stats

₹192.65

-₹4.80(-1.92%)

At close: Jan 08 4:00 PM EST

₹192.65

-₹4.80(-1.92%)

Day’s Range― - ―

52-Week Range₹142.95 - ₹241.00

Previous CloseN/A

Volume1.66M

Average Volume (3M)264.14K

Market Cap

₹201.12B

Enterprise Value₹243.65B

Total Cash (Recent Filing)₹4.08B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta0.83

Next Earnings

May 27, 2026

EPS Estimate

0.84

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)-0.70

Shares Outstanding1,329,248,200

10 Day Avg. Volume501,791

30 Day Avg. Volume264,138

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)3.72

Price to Sales (P/S)3.30

P/FCF Ratio132.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.05

Revenue Forecast (FY)₹90.81B

Bulls Say, Bears Say

Bulls Say

Diversified Business Model (CDMO + Specialty Pharma)Operating both CDMO services and a specialty pharma commercial business creates durable revenue diversification. CDMO work often involves multi-year supply agreements and recurring commercial volumes, providing long-term contract visibility, while specialty products offer margin diversification and market exposure.

Manageable Leverage / Solid Equity BaseA debt-to-equity around 0.6 and a healthy equity ratio indicate balanced capital structure that supports investment and buffers shocks. Manageable leverage improves financial flexibility for capex, capacity additions, or M&A without overly constraining cash flow from operations.

High Gross Margin And Improving Operational EfficiencyA robust gross margin near 65% affords pricing power and room to absorb SG&A and R&D while funding scale. The reported EBIT margin improvement signals operational leverage and efficiency gains that can sustainably enhance cash generation as revenue scales.

Bears Say

Inconsistent Net Profit MarginsVolatile net margins undermine earnings predictability and indicate exposure to variable costs, one-off items, or pricing pressure. Over a multi-month horizon this complicates forecasting free cash flow and can limit reinvestment or steady shareholder returns.

Fluctuating Free Cash Flow / Capex ManagementMaterial swings in free cash flow suggest uneven cash conversion and potential timing of capex or working capital swings. This weakens the company’s ability to fund growth organically, service debt predictably, or commit to consistent shareholder returns.

Reported Revenue Growth WeaknessA large negative reported revenue growth metric signals either recent loss of contracts, one-off revenue declines, or data volatility. Sustained top-line contraction would impair scale economics, jeopardize margin improvements, and strain long-term profitability and investment plans.

Piramal Pharma Limited News

Piramal Critical Care and Blue-Zone Partner to Recycle Waste Anaesthetic Gases

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an announcement. Piramal Critical Care, Inc. and Canada-based Blue-Zone Technologies...

1M ago

Piramal Pharma to Acquire Kenalog Injectable Portfolio from Bristol-Myers Squibb

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical...

1M ago

Piramal Pharma Strengthens Senior Management, Appoints Interim Company Secretary

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited has expanded its senior management...

1M ago

Piramal Pharma Posts Higher Profit Despite Softer Revenue in Q3 FY26

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited’s board has approved the unaudited...

1M ago

Piramal Pharma Posts Muted Q3 FY26 Results but Signals Early Recovery and Continued Expansion

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma Limited reported a 3% year-on-year decline...

1M ago

Piramal Pharma Reshuffles Senior Management and Appoints Interim Company Secretary

An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Piramal Pharma Limited’s board has expanded...

1M ago

Piramal Pharma Posts Q3 Loss as CDMO Weakness Weighs, Signals Early Demand Recovery

The latest update is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma reported a weak performance...

1M ago

Piramal Pharma Revamps Senior Management, Appoints New Compliance Chief

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) just unveiled an update. Piramal Pharma Limited has overhauled its senior management...

1M ago

Piramal Pharma Revamps Senior Management and Key Compliance Role

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced a...

1M ago

Piramal Pharma Shareholders Approve Appointment of Independent Director via Postal Ballot

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced that...

2M ago

PPLPHARMA FAQ

What was Piramal Pharma Limited’s price range in the past 12 months?

Piramal Pharma Limited lowest stock price was ₹142.95 and its highest was ₹241.00 in the past 12 months.

What is Piramal Pharma Limited’s market cap?

Piramal Pharma Limited’s market cap is ₹201.12B.

When is Piramal Pharma Limited’s upcoming earnings report date?

Piramal Pharma Limited’s upcoming earnings report date is May 27, 2026 which is in 77 days.

How were Piramal Pharma Limited’s earnings last quarter?

Piramal Pharma Limited released its earnings results on Jan 28, 2026. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.245 by -₹0.455.

Is Piramal Pharma Limited overvalued?

According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here

What is Piramal Pharma Limited’s EPS estimate?

Piramal Pharma Limited’s EPS estimate is 0.84.

How many shares outstanding does Piramal Pharma Limited have?

Piramal Pharma Limited has 1,329,248,200 shares outstanding.

What happened to Piramal Pharma Limited’s price movement after its last earnings report?

Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.245. Following the earnings report the stock price went up 1.015%.

Which hedge fund is a major shareholder of Piramal Pharma Limited?

Currently, no hedge funds are holding shares in IN:PPLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Piramal Pharma Limited

Piramal Pharma Limited (PPLPHARMA) is a leading global pharmaceutical company based in India, operating under the Piramal Group. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). PPLPHARMA is committed to providing innovative healthcare solutions across various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, leveraging its extensive research and development capabilities.